Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Tappenden, P. orcid.org/0000-0001-6612-2332, Harnan, S. orcid.org/0000-0002-9318-9206, Ren, S. et al. (6 more authors) (2016) Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 Springer Verlag. This is an author produced version of a paper subsequently published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 9 August 2016
  • Published (online): 9 August 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield)
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
NATIONAL INSTITUTE FOR HEALTH RESEARCH14/25/02
Depositing User: Symplectic Sheffield
Date Deposited: 05 Dec 2016 16:39
Last Modified: 12 Aug 2017 09:47
Published Version: http://doi.org/10.1007/s40273-016-0440-x
Status: Published
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-016-0440-x

Share / Export

Statistics